StockNews.com Downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Buy

StockNews.com cut shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a strong-buy rating to a buy rating in a research note issued to investors on Monday.

Other equities analysts have also recently issued reports about the company. Barclays lowered their price target on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Royal Bank of Canada lowered their price target on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a report on Friday, November 1st. BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a report on Friday, November 1st. Evercore ISI lowered their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Finally, Guggenheim increased their price target on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have assigned a buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $1,092.62.

Regeneron Pharmaceuticals Stock Up 1.0 %

Shares of NASDAQ:REGN opened at $824.48 on Monday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The business has a fifty day moving average of $1,035.92 and a two-hundred day moving average of $1,038.36. The stock has a market cap of $90.89 billion, a P/E ratio of 20.40, a PEG ratio of 3.17 and a beta of 0.15. Regeneron Pharmaceuticals has a 52-week low of $783.57 and a 52-week high of $1,211.20.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 7.48% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. Sachetta LLC raised its position in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares in the last quarter. Rakuten Securities Inc. raised its position in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares in the last quarter. Stephens Consulting LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $26,000. Crewe Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $28,000. Finally, Lynx Investment Advisory acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.